Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Novo Nordisk Goes On Offense, Says Its Levemir Insulin Is Safer Bet

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

As news of cancer risk for Lantus sinks in, Novo says it is prepared to pick up orders for patients who want to switch.

You may also be interested in...



Sanofi Counts FDA As New Supporter In Lantus Cancer Scare

Due to "inconsistencies" in European studies, agency is struggling to determine if evidence of cancer risk "truly exists."

Sanofi Counts FDA As New Supporter In Lantus Cancer Scare

Due to "inconsistencies" in European studies, agency is struggling to determine if evidence of cancer risk "truly exists."

Will Sanofi's Lantus Survive Cancer Scare? Studies Suggest a Worrisome Link

But the data also suggest a higher cancer risk could be due to "patient characteristics," and not Lantus itself.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Third Time’s A Charm? US FDA Once Again Proposes Mandatory Consumer Rx Info

Survey Or Shakedown? US Medicaid’s Audacious Negotiation Plan

BIO Notebook: GSK’s Walmsley On M&A; Merck On How Falling Valuations Are Affecting Deals

PBM Reform: Vertical Integration, Specialty Drug Tracking Among Differences In House v. Senate Bills

See All
UsernamePublicRestriction

Register

PS069630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By